re: Ann: Prana's PBT2 Directly Restores N... AD is one of the most expensive diseases to manage
this is a great result to scientifically explain the clinical response and provides validity for it's future use
assuming the safety profile is ok and the drug is easily administered
this should be a block buster
most international drug companies have cut back on research and will happily pick off small biotechs with good molecules
big multinationals have mkt caps like bhp and even $500m
for pbt would be small change
Ann: Prana's PBT2 Directly Restores Neurons C, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $109.5M | |||
| Open | High | Low | Value | Volume |
| 1.3¢ | 1.3¢ | 1.2¢ | $19.63K | 1.513M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 11574308 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 2721776 | 10 |
View Market Depth
| Last trade - 10.00am 15/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |